Bayer challenges Nexavar generic license order in India
(Reuters) - Drugmaker Bayer said on Saturday it had challenged an Indian patents office order that allowed domestic rival Natco Pharma to sell a cheap generic version of the German firm's liver and kidney cancer drug Nexavar in India.
In March, the patents office stripped Bayer of its exclusive rights to sell Nexavar, saying most Indians could not afford it.
It told Natco Pharma to sell the generic drug significantly more cheaply and pay Bayer a 6 percent royalty on sales.
Bayer said it had appealed against the ruling. "We will rigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients," a company spokesman said.
India's decision on Nexavar was seen as a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms.
Separately, Bayer is suing another Indian drugmaker, Cipla, (CIPL.NS) for patent infringement over Nexavar. Cipla has been selling generic Nexavar in India and it has slashed the price of the drug by 75 percent to 6,840 Indian rupees a month.
(Reporting by Kaustubh Kulkarni in Mumbai; Editing by Alistair Lyon)
- Tweet this
- Share this
- Digg this
DAVOS, Switzerland - Central banks have done their best to rescue the world economy by printing money and politicians must now act fast to enact structural reforms and pro-investment policies to boost growth, central bankers said on Saturday.
Trending On Reuters
Barack Obama in India
In a glow of bonhomie, U.S. President Barack Obama and Indian Prime Minister Narendra Modi unveiled plans to unlock billions of dollars in nuclear trade and to deepen defence ties, steps they hope will establish an enduring strategic partnership. Read | Slideshow
- Video: Modi receives Obama at the airport
- "We have a deal" - insurance may unlock India-U.S. atomic trade
- U.S.-China climate deal does not put pressure on India, says Modi
- Obama backs India's solar goals, seeks support for climate talks
- Column - U.S. and India: Two democracies should join to balance China's rise
Indian economic growth forecasts pegged back, despite rate cuts: Reuters Poll. Full Article